Traditionally, pathologic determinations of tumor size, lymph node status, endocrine receptor status, histological grade, and human epidermal growth factor receptor 2 (HER2) expression have driven prognostic predictions and, ultimately, adjuvant therapy recommendations for patients with breast cancer [2]. This evidence concerns the gene ERBB2 and breast carcinoma.